Suppr超能文献

接受静脉注射重组组织型纤溶酶原激活剂治疗的中风患者的极早期活动

Very early mobilization in stroke patients treated with intravenous recombinant tissue plasminogen activator.

作者信息

Arnold Scott M, Dinkins Maryane, Mooney Lesia H, Freeman William D, Rawal Bhupendra, Heckman Michael G, Davis Olivia A

机构信息

Department of Rehabilitative Services, Mayo Clinic, Jacksonville, Florida.

Department of Nursing, Mayo Clinic, Jacksonville, Florida.

出版信息

J Stroke Cerebrovasc Dis. 2015 Jun;24(6):1168-73. doi: 10.1016/j.jstrokecerebrovasdis.2015.01.007. Epub 2015 Apr 11.

Abstract

BACKGROUND

There are limited prospective data on the relative safety of very early mobilization of stroke patients after intravenous recombinant tissue plasminogen activator (IV rtPA) in stroke patients. We hypothesized that very early patient mobilization within 24 hours after IV rtPA administration for acute ischemic stroke would be safe and feasible.

METHODS

The study was a prospective observational safety and feasibility study involving very early mobilization of stroke patients by physical therapy/occupational therapy within 24 hours after IV rtPA administration for treatment of ischemic stroke. A premobilization safety checklist was completed before mobilization to ensure hemodynamic stability. We assessed adverse safety events, including changes in patient symptoms, changes in vital signs, and bleeding complications.

RESULTS

Eighteen patients were enrolled in the study, and informed consent was obtained. One hundred percent of patients were evaluated with a premobilization safety checklist; 72.2% (13 of 18) were mobilized without any adverse event. Eighty-nine percent (42 of 47) of mobilization activities were tolerated without an adverse response. One patient was orthostatic, and 1 patient had transient worsening of hemiparesis. No patient had intracranial bleeding or permanent worsening of neurologic deficits.

CONCLUSIONS

Very early mobilization within 24 hours of ischemic stroke for patients who receive IV rtPA appears to be relatively safe and feasible in most patients. Patients who are mobilized within 24 hours of IV rtPA require detailed neurologic and vital sign monitoring.

摘要

背景

关于静脉注射重组组织型纤溶酶原激活剂(IV rtPA)治疗的中风患者极早期活动的相对安全性,前瞻性数据有限。我们假设,对于急性缺血性中风患者,在静脉注射rtPA后24小时内极早期让患者活动是安全可行的。

方法

本研究是一项前瞻性观察性安全性和可行性研究,涉及在静脉注射rtPA治疗缺血性中风后24小时内通过物理治疗/职业治疗对中风患者进行极早期活动。在活动前完成一份活动前安全检查表,以确保血流动力学稳定。我们评估了不良安全事件,包括患者症状变化、生命体征变化和出血并发症。

结果

18名患者纳入本研究并获得知情同意。100%的患者接受了活动前安全检查表评估;72.2%(18例中的13例)患者在活动时未出现任何不良事件。89%(47次活动中的42次)的活动耐受良好,未出现不良反应。1例患者出现体位性低血压,1例患者偏瘫短暂加重。没有患者发生颅内出血或神经功能缺损永久性恶化。

结论

对于接受静脉注射rtPA的缺血性中风患者,在24小时内极早期活动在大多数患者中似乎相对安全可行。在静脉注射rtPA后24小时内活动的患者需要详细的神经学和生命体征监测。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验